The Quark siRNA platform allows our R&D teams to continue discovering new molecules and to develop new investigational drugs independently or through collaborations to address significant unmet medical needs. In addition to our late-stage QPI-1002 and QPI-1007 products, our early-stage pipeline includes siRNAs for a range of indications in dermatology, ophthalmology, ENT, respiratory and CNS.